In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation
A27. EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined